UniPharma Co., Ltd. (TPEX:6621)

UniPharma Statistics

Total Valuation

UniPharma has a market cap or net worth of TWD 426.01 million. The enterprise value is 294.19 million.

Market Cap	426.01M
Enterprise Value	294.19M

Important Dates

The next estimated earnings date is Wednesday, May 20, 2026.

Earnings Date	May 20, 2026
Ex-Dividend Date	n/a

Share Statistics

UniPharma has 35.50 million shares outstanding.

Current Share Class	35.50M
Shares Outstanding	35.50M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.21%
Owned by Institutions (%)	n/a
Float	28.45M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.69
PB Ratio	1.70
P/TBV Ratio	1.72
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-7.58
EV / Sales	3.24
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.50

Financial Position

The company has a current ratio of 6.19, with a Debt / Equity ratio of 0.05.

Current Ratio	6.19
Quick Ratio	5.14
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.63
Interest Coverage	-357.42

Financial Efficiency

Return on equity (ROE) is -13.93% and return on invested capital (ROIC) is -33.52%.

Return on Equity (ROE)	-13.93%
Return on Assets (ROA)	-7.97%
Return on Invested Capital (ROIC)	-33.52%
Return on Capital Employed (ROCE)	-15.38%
Weighted Average Cost of Capital (WACC)	3.75%
Revenue Per Employee	2.93M
Profits Per Employee	-1.25M
Employee Count	31
Asset Turnover	0.29
Inventory Turnover	1.67

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.89% in the last 52 weeks. The beta is -0.07, so UniPharma's price volatility has been lower than the market average.

Beta (5Y)	-0.07
52-Week Price Change	-14.89%
50-Day Moving Average	12.49
200-Day Moving Average	13.02
Relative Strength Index (RSI)	37.45
Average Volume (20 Days)	164,716

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, UniPharma had revenue of TWD 90.79 million and -38.84 million in losses. Loss per share was -1.09.

Revenue	90.79M
Gross Profit	47.55M
Operating Income	-40.03M
Pretax Income	-38.84M
Net Income	-38.84M
EBITDA	-36.73M
EBIT	-40.03M
Loss Per Share	-1.09

Balance Sheet

The company has 144.62 million in cash and 12.80 million in debt, with a net cash position of 131.82 million or 3.71 per share.

Cash & Cash Equivalents	144.62M
Total Debt	12.80M
Net Cash	131.82M
Net Cash Per Share	3.71
Equity (Book Value)	251.24M
Book Value Per Share	7.08
Working Capital	162.15M

Cash Flow

In the last 12 months, operating cash flow was -19.15 million and capital expenditures -1.14 million, giving a free cash flow of -20.29 million.

Operating Cash Flow	-19.15M
Capital Expenditures	-1.14M
Free Cash Flow	-20.29M
FCF Per Share	-0.57

Margins

Gross margin is 52.38%, with operating and profit margins of -44.09% and -42.78%.

Gross Margin	52.38%
Operating Margin	-44.09%
Pretax Margin	-42.78%
Profit Margin	-42.78%
EBITDA Margin	-40.46%
EBIT Margin	-44.09%
FCF Margin	n/a

Dividends & Yields

UniPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-9.12%
FCF Yield	-4.76%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

UniPharma has an Altman Z-Score of 7.75 and a Piotroski F-Score of 4.

Altman Z-Score	7.75
Piotroski F-Score	4